Advanced Malignancy Clinical Trial
Verified date | July 2014 |
Source | University of Vermont |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Outcomes after in-hospital cardiopulmonary resuscitation (CPR) are very poor, particularly in patients with oxygen dependent chronic obstructive pulmonary disease (COPD) or metastatic cancer. Recent work found that in-hospital CPR is being performed more often before death with unchanging survival and that fewer CPR survivors are being discharged home, thus suggesting that CPR is increasingly performed without benefit and that the burden of this ineffective treatment is increasing. Unlike other medical procedures, CPR has become the default provided to all patients even those with tremendously poor outcomes. It is time to change the paradigm of CPR. Through comparing an innovative "informed assent" approach toward in-hospital CPR (informing patients that their underlying chronic illness makes outcomes of CPR so poor that CPR is not performed while allowing them to disagree) versus usual care in a group of chronically ill patients with reduced life expectancy, the investigators aspire to demonstrate that CPR delivery can be reduced. And in addition that DNR status increases, while preserving patient quality of life and decreasing the burden of this ineffective treatment to both patients and families. If effective, this informed assent intervention has the potential to revolutionize how the investigators discuss CPR with the investigators chronically ill patients.
Status | Completed |
Enrollment | 29 |
Est. completion date | April 2014 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years or older - Oxygen dependent COPD or Advanced Malignancy - Life expectancy of less than two years Exclusion Criteria: - Subjects who have already firmly decided to undergo CPR - Subjects enrolled in a hospice program - Subjects unable to speak English - Subjects incapable of making their own decisions at the time of enrollment - Subjects cared for by the study investigator |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | University of Vermont and Fletcher Allen Health Care | Burlington | Vermont |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Vermont |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiopulmonary Resuscitation Preference | The primary outcome will be the difference in the proportion of patients in the informed assent intervention and informational brochure groups reporting preferences to be DNR (do not rescusitate). | Within couple of hours before the intervention and immediately (up to 2 days) after the intervention | No |
Secondary | Depression | Patients' and family members' symptomes of depression will be measured by the PHQ-8 questionnaire. | Baseline (day of intervention) and 2 weeks after intervention | No |
Secondary | Anxiety | Patients and families will complete the GAD-7 questionnaire, a measure of generalized anxiety disorder. | Baseline (day of intervention) and two weeks after intervention | No |
Secondary | Physician Order for Life Sustaining Treatment (POLST) | Participants who expressed a preference to be DNR will be asked to complete a POLST form by their physician. It will also be explained that this can be changed any time the status changes. | Baseline (day of intervention) and 2 weeks after intervention | No |
Secondary | DNR status preference | The difference in DNR status preference between patients in the control and invervention group at two weeks after the intervention. | Two weeks after the intervention | No |
Secondary | Report on acceptability of the informed assent approach | The following questions will be asked: How helpful was this approach to discussing CPR with respect to CPR decisions? Would you recommend this approach to discussing CPR for other patients who have serious illnesses? |
Within couple of hours (up to 2 weeks) after intervention | No |
Secondary | Assessment of DNR status change or intervention follow-up from primary physician | Contact the physician for each patient at 3 months after the study visit to determine whether there are changes in the DNR status or if the physician has talked with the patients about the status since the study visit. | Three months after the intervention | No |
Secondary | Resource utilization | Record resource utilization for participants that includes hospitalizations, ICU care, use of hospice etc by medical record review. | Up to 6 months after intervention or until death | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00978926 -
A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies
|
N/A | |
Completed |
NCT01444404 -
A Study of AMG 820 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00428545 -
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
|
Phase 1 | |
Completed |
NCT02743637 -
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
|
Phase 1 | |
Completed |
NCT01253707 -
A Study of AMG 337 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01723020 -
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
|
Phase 1 | |
Completed |
NCT00813384 -
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00974896 -
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02110355 -
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT02978482 -
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00858377 -
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04216082 -
A Study of Anlotinib in Subjects With Advanced Malignancy
|
Phase 2 | |
Terminated |
NCT02437916 -
Safety Study of AMG 228 to Treat Solid Tumors
|
Phase 1 | |
Terminated |
NCT01231347 -
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
|
Phase 3 | |
No longer available |
NCT01945164 -
XL999 Administered Intravenously to a Subject With Advanced Malignancies
|
N/A | |
Completed |
NCT03875157 -
Study of IBI318 in Participants With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT02016729 -
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
|
Phase 1 |